To schedule a new patient appointment call 844-CANCERNJ (844-226-2376)
To schedule a follow-up appointment call 732-235-7615
For all other inquiries call 732-235-2465.
I am thrilled to be a member of the Rutgers Cancer Institute of New Jersey as the Deputy Director for Clinical Services; System Director of Medical Oncology and Oncology Lead for the Combined Medical Group with RWJBarnabas Health (RWJBH); and Associate Vice Chancellor for Clinical Innovation and Data Analytics, within Rutgers Health at Rutgers University. Rutgers Cancer Institute is one of only 56 cancer centers recognized nationally and New Jersey’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center. Our mission is to deliver comprehensive and compassionate cancer care across the health system with access to worldwide expertise and innovative cancer therapies not available elsewhere in the state.
I completed a fellowship in hematology/oncology at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois, where I also remained as a faculty member altogether for 11 years. Most recently, I served as the director of the Cancer Center at Tufts Medical Center in Boston, chief of their division of hematology/oncology, and Professor of Medicine at Tufts University School of Medicine.
My clinical expertise and research interests are focused in the field of lymphoid malignancies, in particular Hodgkin lymphoma and non-Hodgkin lymphoma. Over the past 20 years, I have been the principal investigator of more than 100 cancer clinical trials that have included phase I, II, and III studies, and I help lead several national and global health outcomes and data analytics projects in lymphoma. Collectively, my research has been continuously funded by the National Institutes of Health (NIH) since 2005. This has resulted in 400+ research abstract presentations at national and international cancer symposiums, 230+ manuscripts in peer-reviewed publications, and 40+ book chapters with an emphasis on the prognosis, treatment, and health outcomes of cancer.
Nationally, I am a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee, and an ad hoc member of additional clinical and scientific committees for the NIH, Cancer Therapy Evaluation Program (CTEP), and the Food and Drug Administration (FDA). I was an associate editor for the British Journal of Haematology for 8 years and now serve as the inaugural editor-in-chief of the gold open-access journal, eJHaem. I am Vice-Chair of the Lymphoma Committee for the ECOG-ACRIN cancer research group; Co-Chair of the Big 10 Cancer Research Consortium lymphoma working group; and a re-elected member and the Chair-elect for the esteemed North American Scientific Advisory Board (SAB) for the Lymphoma Research Foundation that is comprised of 45 world-renowned lymphoma experts. Finally, I help lead a multitude of regional, national, and international educational forums and scientific events.
Rutgers Cancer Institute has a rich history of conducting state-of-the-art and groundbreaking cancer research, and together with RWJBH and Rutgers Health, offers international expertise, multidisciplinary clinical care, leading-edge cancer treatments, and unparalleled resources for cancer patients and their families all close to home. I am honored to be a member of the Rutgers Cancer Institute and a leader of the RWJBH oncology service line working alongside the multitude of outstanding oncology providers providing compassionate and expert cancer care throughout the state of New Jersey and beyond.
September 10, 2024
Good.
September 3, 2024
Extremely knowledgeable provider. He made me feel calmer.
August 20, 2024
Dr. Evens and Tara McCabe his NP have been incredibly helpful in managing my lymphoma.
June 25, 2024
Great doctor.
May 14, 2024
Good.
April 11, 2024
Very knowledgeable, took the time to explain everything to me, & really VERY GOOD bedside manners. EXCELLENT DOCTOR! Listened to what I had to say.
April 11, 2024
Dr. Evans saved my life. He's a hero to me!
April 3, 2024
Dr. Evens was excellent.
February 19, 2024
The entire team in Dr. Evens office, along with Dr. Evens have excellent patient skills. I am never rushed through an appt. They give me time to express myself.
February 1, 2024
My provider is very approachable.
January 25, 2024
Dr. Evens and his staff were amazing in their care of my health issues. They are amazing and my family is very grateful.
January 3, 2024
Dr. Evens listens, shows concern, discusses option and is caring. He's wonderful.
December 29, 2023
We often discuss the new developments in lymphoma research and when new developments may be available.
Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with your insurance company they are still a participating plan prior to receiving services or care. Each plan is different and some provide different levels of coverage that could make a difference in your out-of-pocket costs. It is always best for the patient receiving care to contact their insurance company to obtain more information.
Protecting your Heart Before, During and After Cancer Treatment
Cardiac care is not likely the first thing on a patient’s mind when fighting cancer, however, cancer and cardiovascular issues are closely linked. Read more
.jpeg)
$3.5 Million NIH Grant will Help Harness Worldwide Big Data to Enhance Decision Support in Hodgkin Lymphoma
Rutgers Cancer Institute and Tufts Medical Center are collaborating on work that is unifying global multi-source big data in order to enhance clinical decision support for improved acute and long-term outcomes for Hodgkin lymphoma patients around the world. Read more
Investigators Develop Model to Predict Overall Survival in Adults Diagnosed with Advanced Stage Hodgkin Lymphoma
Investigators from Rutgers Cancer Institute along with Tufts Medical Center, developed and validated the Advanced-stage Hodgkin lymphoma International Prognostication Index (A-HIPI). A-HIPI is a state-of-the-art clinical decision model to predict five-year progression-free and overall survival in adults with advanced-stage classic Hodgkin lymphoma using comprehensive individual patient data from international clinical trials and large prospective cancer registries. Learn More